Genome sequencing Ambry Genetics launched GenomeNext and GenomeReveal, a whole genome sequencing solution combining WGS, RNA analysis, and ongoing reanalysis to improve rare-disease diagnosis. This presents a cross-sell opportunity to healthcare providers seeking comprehensive diagnostic workflows and ongoing data reanalysis services.

CARE program CARE, Ambry's health informatics and education program, has won a major award, signaling strong capabilities in data management, interpretation, and clinician-facing results. This positions the company to upsell advanced informatics solutions and expanded reporting to hospital systems and insurers.

Tempus ecosystem As a Tempus company with a growing partner network including academic, corporate, and pharmaceutical collaborators, Ambry has access to multi-institution collaborations and data partnerships that can be leveraged for co-development deals, comparative studies, and expanded access programs.

Security and trust Past phishing incident highlights the importance of robust security and patient data protection. This creates an entry point to position enhanced security offerings, compliant data-sharing workflows, and government/clinical partner assurances as a differentiator in sales conversations.

Growth alignment Recent partnerships and regulatory-leaning expansions in rare disease diagnostics indicate a market push toward integrated genomic testing with analytics. This suggests opportunities to target payer conversations, hospital networks, and specialty clinics seeking scalable, end-to-end genomic testing and reanalysis capabilities.